Navigation Links
Researchers identify potential new strategy to treat ovarian cancer
Date:4/28/2014

Scientists studying cancerous tumour tissues in a laboratory believe they have identified a potential new strategy to treat ovarian cancer which affects around 7,000 women in the UK each year.

Recently developed drugs have increased patient survival rates by targeting a tumour's blood vessels that supply essential nutrients and oxygen to cancer cells.

However, many patients go on to develop resistance to these therapies and grow new blood vessels that spread the cancer again.

A team from The University of Manchester part of the Manchester Cancer Research Centre - say blocking several avenues that tumour cells use to escape eradication at the same time is now the way forward rather than current drugs, which target only one molecule.

The research gives scientists the opportunity to develop new anticancer drugs that target ovarian tumour growth through the inhibition of the development of new tumour blood vessels.

Ovarian cancer is the deadliest of all gynaecological cancers, and since the majority of patients are diagnosed when the disease is at an advanced stage, prognosis is generally poor. Currently 7,000 women are diagnosed with the disease in the UK each year. Of those, more than 4,000 are not expected to survive but if women are diagnosed earlier 90% of those cases could beat the disease.

Scientists looked at the role of a particular set of molecules in controlling the activity of growth factors, proteins that are responsible for the stimulation of blood vessel growth.

Dr Egle Avizienyte, who co-led the research with Professor Gordon Jayson, said: "We know that a molecule called heparan sulphate (HS) is involved in blood vessel growth through facilitating interactions between the growth factors and their receptors that induce the development of new blood vessels. This is controlled by proteins known as HS6STs which regulate HS structure. By knocking down these proteins reducing their levels in cancer cells we were able to reduce activity of growth factors and stop ovarian cancer cells inducing the development of new blood vessels."

The studies in tumour tissue in the laboratory showed that reducing HS6STs led to a reduction of tumour growth.

Professor Gordon Jayson, who leads the research group, said: "This knowledge gives us the opportunity to develop new anticancer drugs aimed against these growth factors. Targeting multiple factors and blocking several avenues that tumour cells use to escape eradication at the same time may be a better strategy than current drugs, which target only one molecule."


'/>"/>

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related medicine news :

1. NYU Steinhardt researchers to study why male millennials risk HIV transmission
2. Researchers generate immunity against tumor vessel protein
3. Researchers at LSTM part of the international team to sequence the tsetse genome
4. Oxygen diminishes the hearts ability to regenerate, researchers discover
5. Finnish team of researchers finds a mutation in a tumor of the jaw
6. Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches
7. Life stressors trigger neurological disorders, researchers find
8. Penn researchers find link between sleep and immune function in fruit flies
9. Penn Medicine researchers uncover hints of a novel mechanism behind general anesthetic action
10. CU researchers discover target for treating dengue fever
11. BUSM researchers find anti-seizure drug may reduce alcohol consumption
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... 2017 , ... PurhealthRX , a leading Health and Nutrition Company, is ... to full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing ... easily incorporated into liquid products, while reducing costs to end users. , The team ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology: